Observational studyHaematologica2022
Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study.
Registry-linked trialAbstract readObservational Study
In one paragraph
Observational study in Haematologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07021677 (Daratumumab for Minimal Residual Disease Eradication in T-Acute Lymphoblastic Leukemia - A Phase 2 Study), which is not on this map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Daratumumab for Minimal Residual Disease Eradication in T-Acute Lymphoblastic Leukemia - A Phase 2 Study
Who cites it
25 citing papers in PubMed.
- Allo-defensive, multiplex base-edited, anti-CD38 CAR T cells for 'off-the-shelf' immunotherapy.Haematologica · 2026Article
- Current and emerging maintenance strategies after stem cell transplantation in children and adolescents with acute leukemias.Molecular therapy. Oncology · 2026Review
- Daratumumab-based salvage therapy enables umbilical cord blood transplantation in multiline refractory, elderly T-lymphoblastic lymphoma: a case report.Frontiers in immunology · 2026Article
- Targeting CD38 in relapsed /refractory T-cell acute lymphoblastic leukemia/lymphoma: A systematic review of daratumumab-based therapy.Therapeutic advances in hematology · 2026Review
- Where do immunotherapies stand in management of acute leukemia in adults?Hematology. American Society of Hematology. Education Program · 2025Review
- Leveraging the heterogeneity of the NK cell repertoire for the development of immunotherapies for acute leukemia.Journal of translational medicine · 2025Review
- Article
- Daratumumab plus bortezomib and dexamethasone as a bridge to allogeneic transplantation in refractory T-cell lymphoblastic lymphoma.Annals of hematology · 2025Article
- Review
- CD38 in the pathobiology of cutaneous T-cell lymphoma and the potential for combination therapeutic intervention.Leukemia · 2025Article
- Review
- A complete response with daratumumab, venetoclax, azacitidine and dexamethasone in a heavily pre-treated, chemo-refractory early T-precursor acute lymphoblastic leukemia/lymphoma patient.Annals of hematology · 2025Article
- The clinical efficacy of a daratumumab-based regimen in relapsed/refractory acute leukemia: a single-center experience.Annals of hematology · 2024Article
- Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia.Haematologica · 2024Review
- Daratumumab and brentuximab vedotin combination therapy in T-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and allogeneic stem cell transplant.Haematologica · 2024Article
- Frequent, high density expression of surface CD38 as a potential therapeutic target in adult T-lineage acute lymphoblastic leukemia.Haematologica · 2024Article
- Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia.Blood advances · 2024Review
- Advancing Diagnostics and Therapy to Reach Universal Cure in Childhood ALL.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Review
- Daratumumab-a novel treatment strategy in relapsed/refractory acute leukemia.Annals of hematology · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Marco CerranoDivisione di Ematologia, Dipartimento di Oncologia, AOU Città della Salute e della Scienza, Torino, Italy. cerranomarco@gmail.com.
Massimiliano BonifacioUOC di Ematologia, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy; Dipartimento di Medicina, Sezione di Ematologia, Università di Verona, Italy.
Matteo OliviDivisione di Ematologia, Dipartimento di Oncologia, AOU Città della Salute e della Scienza, Torino, Italy; Dipartimento di Biotecnologie Molecolari e Scienze per la Salute, Università di Torino, Torino, Italy.
Antonio CurtiIRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
Michele MalagolaUniversità di Brescia, Unità Operativa di Ematologia e Centro Trapianti, ASST Spedali Civili di Brescia, Italy.
Michelina DargenioUnità Operativa di Ematologia e Trapianto, Ospedale Vito Fazzi, Lecce, Italy.
Anna Maria ScattolinUnità Operativa di Ematologia e Trapianto, Ospedale dell'Angelo, Mestre, Italy.
Cristina PapayannidisIRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
Fabio ForghieriUnità Operativa Complessa di Ematologia, Azienda Ospedaliero-Universitaria di Modena, Italy.
Carmela GurrieriUO Ematologia ed Immunologia Clinica, Azienda Ospedale-Università Padova, Italy.
Ilaria TanasiUOC di Ematologia, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy; Dipartimento di Medicina, Sezione di Ematologia, Università di Verona, Italy.
Patrizia ZappasodiUnità Operativa di Ematologia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Roberta La StarzaUnità Operativa di Ematologia e Trapianto, AOU-Ospedale S. Maria della Misericordia, Perugia, Italy.
Nicola Stefano FracchiollaUOC Ematologia Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milano, Italy.
Patrizia ChiusoloDipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy; Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Roma, Italy.
Luisa GiacconeDipartimento di Biotecnologie Molecolari e Scienze per la Salute, Università di Torino, Torino, Italy; Unità di Trapianto Allogenico di Cellule Staminali, Dipartimento di Oncologia, A.O.U. Città della Salute e della Scienza, Torino, Italy.
Maria Ilaria Del PrincipeEmatologia, Dipartimento di Biomedicina e Prevenzione, Università di Roma Tor Vergata, Roma, Italy.
Fabio GiglioUnità Operativa di Ematologia e Trapianto di Midollo Osseo, IRCCS Ospedale San Raffaele, Milano, Italy.
Marzia DefinaUnità Operativa Complessa di Ematologia, AOUS, Università di Siena, Siena, Italy.
Claudio FavreUnità Operativa di Oncologia ed Ematologia Pediatrica, Ospedale Pediatrico Meyer, Firenze, Italy.
Carmelo RizzariUnità Operativa di Ematologia Pediatrica, Università di Milano-Bicocca, Fondazione MBBM, Monza, Italy.
Barbara CastellaLaboratorio Analisi, AO S. Croce e Carle, Cuneo, Italy.
Giovanni PizzoloUOC di Ematologia, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy; Dipartimento di Medicina, Sezione di Ematologia, Università di Verona, Italy.
Felicetto FerraraUOC di Ematologia, AORN Cardarelli, Napoli, Italy.
Sabina ChiarettiEmatologia, Dipartimento di Medicina Traslazionale e di Precisione, Università Sapienza, Roma, Italy.
Robin FoàEmatologia, Dipartimento di Medicina Traslazionale e di Precisione, Università Sapienza, Roma, Italy. rfoa@bce.uniroma1.it.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antibodies, MonoclonalPrecursor Cell Lymphoblastic Leukemia-LymphomaHumansRetrospective StudiesAntibodies, Monoclonaldaratumumab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
NCT07021677ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.